RemeGen Co., Ltd. (9995.HK) HKSE

Currency In HKD

RemeGen Co., Ltd.

Address

58 Middle Beijing Road

Yantai,

China

Phone

86 53 56357 3672

Website

https://www.remegen.com

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

3048

First IPO Date

November 09, 2020

Key Executives

Name	Title	Pay	Year Born
Jianmin Fang	Co-Founder, Chief Executive Officer, GM, Member of Scientific Advisory Board & Executive Director	8.55M	1962
Jian Lin	Executive Director	890,821	1955
Zhulun Wang	Chief Scientific Officer	0	N/A
Marie Zhu	Chief Technical Officer	0	N/A
Ming Shi	Chief Medical Officer	0	1967
Xiaoming Yang	Chief Manufacturing Officer	0	1964
Kaisheng Huang	Chief Operating Officer	0	N/A
Qingkai Wen	Executive Director & Board Secretary	0	1966
Weidong Wang	Co-Founder & Executive Chairman	0	1959
Shaojing Tong	Chief Financial Officer & Joint Company Secretary	0	1971

Description

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.